KB 002
Alternative Names: KB002Latest Information Update: 08 Aug 2017
At a glance
- Originator Ludwig Institute for Cancer Research
- Developer KaloBios Pharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Immunosuppressants; Macrophage inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Asthma; Rheumatoid arthritis